This statistic shows the amount of registrations of newly diagnosed cases of stomach cancer in England in 2022, by age group. With a total of *** cases in 2022, the age group most affected by stomach cancer in terms of the number of cases was men aged 75 to 79 years. It should be noted that the number of people in England in each age group varies and is therefore not necessarily a reflection of susceptibility to this cancer.

This dataset is designed for the task of gastric cancer detection using advanced machine learning models. It contains clinical, demographic, diagnostic, and molecular data gathered from diverse healthcare sources, specifically focusing on gastric cancer (GC) patients. The dataset is sourced from clinical studies, medical imaging, and genomics, offering a rich collection of features that can be leveraged to identify patterns and predict cancer risks, including genetic, environmental, and lifestyle-related factors.

The dataset consists of comprehensive records from gastric cancer patients, detailing their medical history, diagnostic results, and various imaging and molecular profiles. It is particularly useful for research in AI-based detection and diagnosis of gastric cancer, as well as in predictive modeling for clinical decision-making.

This study employed a Zurich, Switzerland, specialized research cooperative dataset \cite{33}. This collection includes patient information from regional medical facilities and research labs known for cancer and molecular diagnostics. It offers varied and high-quality data from real-world stomach cancer diagnostic and clinical procedures. The data gathering procedure followed strong ethical and privacy norms to protect patient data. Gastric cancer research records were validated to ensure relevance and correctness, making them trustworthy for AI-driven medical applications. The dataset contains demographic, clinical, and molecular information important to healthcare analytics and represents the newest advances. A stable basis for AI-based stomach cancer diagnosis, this dataset allows prediction models to be tested and validated in real life.

Features The dataset includes the following columns, each representing key variables related to gastric cancer detection and patient characteristics:

Age:

Type: Numerical Description: Age of the patient at the time of diagnosis or evaluation. Gender:

Type: Categorical (Male/Female) Description: The gender of the patient. Ethnicity:

Type: Categorical Description: Ethnic background of the patient. Geographical Location:

Type: Categorical Description: The geographical location where the data was collected (e.g., country, region). Family History:

Type: Binary (Yes/No) Description: Whether the patient has a family history of cancer (Yes/No). Smoking Habits:

Type: Binary (Yes/No) Description: Whether the patient smokes (Yes/No). Alcohol Consumption:

Type: Binary (Yes/No) Description: Whether the patient consumes alcohol (Yes/No). Helicobacter Pylori Infection:

Type: Binary (Yes/No) Description: Whether the patient has a Helicobacter pylori infection, a known risk factor for gastric cancer. Dietary Habits:

Type: Categorical Description: Dietary patterns of the patient, such as high salt intake or high-fat diet. Existing Conditions:

Type: Categorical Description: Pre-existing medical conditions such as diabetes, gastritis, or hypertension. Endoscopic Images:

Type: Categorical (Normal/Abnormal) Description: Results from endoscopy imaging of the gastric mucosa. Normal or abnormal findings. Biopsy Results:

Type: Categorical (Positive/Negative) Description: The result of biopsy testing. Positive or negative for cancer. CT Scan:

Type: Categorical (Normal/Abnormal) Description: Imaging results from a CT scan used to detect potential tumors in the stomach. Mature miRNA Accession:

Type: Categorical Description: Accession number of the mature miRNA, a biomarker used in cancer diagnosis. Mature miRNA ID:

Type: Categorical Description: Identifier for the mature miRNA sequence. Target Symbol:

Type: Categorical Description: Symbol of the target gene associated with the miRNA. Target Entrez:

Type: Categorical Description: Unique Entrez Gene ID for the target gene. Target Ensembl:

Type: Categorical Description: Unique Ensembl Gene ID for the target gene. DIANA microT Score:

Type: Numerical Description: Prediction score for miRNA-target interaction based on the DIANA algorithm. ElMMo Score:

Type: Numerical Description: Confidence score for miRNA-target predictions. Microcosm Score:

Type: Numerical Description: Interaction score based on the Microcosm prediction algorithm. MiRanda Score:

Type: Numerical Description: Score representing miRNA-target alignment from the MiRanda algorithm. miRDB Score:

Type: Numerical Description: Confidence score from the miRDB database indicating the strength of miRNA-target interaction. PicTar Score:

Type: Numerical Description: Predicted miRNA-target interaction score from the PicTar algorithm. PITA Score:

Type: Numerical Description: Prediction score based on target accessibility. TargetScan Score:

Type: Numerical Description: miRNA target prediction score from the TargetScan algorithm. Predicted Sum:

Type: Numerical Description: Aggregated prediction confidence score across multiple algorithms. All...

Legacy unique identifier: P00670

This statistic shows the rate of registrations of newly diagnosed cases of stomach cancer per 100,000 population in England in 2020, by region and gender. With a rate of 16.3 newly diagnosed males with stomach cancer and 8.4 females per 100,000 population in 2020, the region most affected by stomach cancer in terms of number of cases was that of the North East.

In Germany, the number of cases of stomach cancer from 2019 to 2022 were considerably higher for men, amounting to over ************* cases in 2022. Conversely, women reported around *** thousand cases during the same period. This statistic depicts the number of stomach cancer cases in Germany between 2019 and 2022, by gender.

This statistic shows the death rate of stomach cancer in the United States from 1999 to 2021. The maximum death rate in the given period was *** per 100,000 inhabitants in 1999. The minimum death rate stood at *** in 2021.

Deaths from stomach cancer - Directly age-Standardised Rates (DSR) per 100,000 population Source: Office for National Statistics (ONS) Publisher: Information Centre (IC) - Clinical and Health Outcomes Knowledge Base Geographies: Local Authority District (LAD), Government Office Region (GOR), National, Primary Care Trust (PCT), Strategic Health Authority (SHA) Geographic coverage: England Time coverage: 2005-07, 2007 Type of data: Administrative data

In 2019, nearly *** percent of all men, as well as more than *** percent of all women diagnosed with stomach cancer were between 65 to 69 years old. Meanwhile, only **** percent of all boys and **** percent of all girls and teens under 19 years old had the same condition.

ObjectivesStomach cancer is one of the leading causes of cancer death, and its epidemiologic characteristics are regionally heterogeneous worldwide. The BRICS nations (Brazil, Russian Federation, India, China, and South Africa) have markedly increasing influences on the international stage. We aim to investigate time trends in stomach cancer mortality among the BRICS countries from 1982 to 2021.MethodsData for this study were obtained from the Global Burden of Disease (GBD) 2021 public dataset to investigate the deaths, all-age mortality rate, and age-standardized mortality rate (ASMR) of stomach cancer. The age-period-cohort (APC) model was employed to estimate net drift, local drift, age-specific curves, and period (cohort) relative risks, and the Bayesian generalized linear model was employed to evaluate the relationship between food intake and mortality rate.ResultsIn 2021, there were approximately 572,000 stomach cancer deaths across the BRICS, accounting for 59.9% of global death. Russian Federation exhibited the most significant reduction in ASMR of stomach cancer among the BRICS. In contrast, China continued to report the highest number of stomach cancer deaths. The risk of mortality associated with stomach cancer exhibited a marked increase with advancing age, both within these countries and at the global level. PUFA, sodium, calcium and trans fat may have an impact on the mortality rate of stomach cancer. Favorable trends in period and birth cohort effects were observed in these five nations over the past decades.ConclusionBRICS countries have made varying progress in reducing stomach cancer mortality. Given the diverse environments, it is recommended to progressively develop customized stomach cancer prevention strategies, utilizing available resources. Healthcare services should be extended to all age groups, with a particular emphasis on vulnerable populations.

This statistic shows the rate of mortality to stomach cancer incidence in England in 2016, by region and gender. Stomach cancer, which is also known as gastric cancer, is cancer which begins in the stomach, particularly the lining of the stomach. In this year, in the West Midlands ** percent of males and ** percent of females who were diagnosed died as a result of stomach cancer, this was the highest recorded rate among females.

BackgroundStomach cancer is a significant health problem in many countries. But healthcare needs of adolescents and young adults (AYAs) stomach cancer patients have been historically neglected. An accurate appraisal of the burden of AYA stomach cancer is crucial to formulating effective preventive strategies. In this study, we report the most recent estimates of AYA stomach cancer burden concerning socio-demographic index (SDI) in 204 countries and territories between 1990 and 2019.MethodsEstimates from the Global Burden of Disease study 2019 were used to analyze incidence, mortality, and disability-adjusted life years (DALYs) due to AYA stomach cancer at global, regional, and national levels. Association between AYA stomach cancer burden and SDI were investigated. All estimates are reported as absolute numbers and age-standardized rates, which were standardized to the GBD world population and reported per 100,000 population.ResultsIn 2019, there were 49,000 incident cases, 27,895 deaths, and 1.57 million DALYs due to AYA stomach cancer globally. The highest age-standardized incidence rate occurred in East Asia [2.42 (women) and 4.71 (men) per 100,000 person-years] and high-income Asia Pacific [3.16 (women) and 2.61 (men) per 100,000 person-years]. Age-standardized death [1.53 (women) and 2.65 (men) per 100,000 person-years] and DALY [150.96 (women) and 87.13 (men) per 100,000 person-years] rates were highest in Oceania. Compared with 1990, in 2019 more than 1,075 more incident cases of AYA stomach cancer were estimated with a decrease of 7,784 deaths. Despite the increase in absolute number of incident cases, the worldwide age-standardized rates of AYA stomach cancer (incidence, deaths, and DALYs) have declined since 1990. The drop in the disease burden was associated with an improved SDI. Globally, 24.41% of the age-standardized DALYs were attributable to a high-sodium diet in both sexes combined, and 0.57% of the age-standardized DALYs were attributable to smoking in men.ConclusionThe global burden of AYA stomach cancer is substantial, especially in developing regions. Capacity-building activities for AYA stomach cancer will benefit the younger generation and population health worldwide.

Years of Life Lost (YLL) as a result of death from stomach cancer - Directly age-Standardised Rates (DSR) per 100,000 population Source: Office for National Statistics (ONS) Publisher: Information Centre (IC) - Clinical and Health Outcomes Knowledge Base Geographies: Local Authority District (LAD), Government Office Region (GOR), National, Primary Care Trust (PCT), Strategic Health Authority (SHA) Geographic coverage: England Time coverage: 2005-07, 2007 Type of data: Administrative data

As of 2024, around ****** people were living with a diagnosis of stomach cancer in Italy. Most of them were men, with ****** cases. The graph presented shows the number of people living with a diagnosis of stomach cancer in Italy as of 2024, by gender.

According to Cognitive Market Research, the global Stomach Cancer and Gastric Cancer Treatment market size is USD 4124.2 million in 2024. It will expand at a compound annual growth rate (CAGR) of 13.20% from 2024 to 2031.

North America held the major market share for more than 40% of the global revenue with a market size of USD 1649.68 million in 2024 and will grow at a compound annual growth rate (CAGR) of 11.4% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 1237.26 million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 948.57 million in 2024 and will grow at a compound annual growth rate (CAGR) of 15.2% from 2024 to 2031.
Latin America had a market share for more than 5% of the global revenue with a market size of USD 206.21 million in 2024 and will grow at a compound annual growth rate (CAGR) of 12.6% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 82.48 million in 2024 and will grow at a compound annual growth rate (CAGR) of 12.9% from 2024 to 2031.
In 2023, the injectable segment led the gastric cancer therapy market

Market Dynamics of Stomach Cancer and Gastric Cancer Treatment Market

Key Drivers for Stomach Cancer and Gastric Cancer Treatment Market

Rising Incidence of Stomach Cancer

The increased incidence of stomach cancer has a substantial impact on the market, stimulating demand for a variety of medical interventions and therapies. The number of identified cases rises in response to the need for specific diagnostic techniques, therapies, drugs, and surgical methods to combat the condition. Because of this rising demand, pharmaceutical companies are motivated to expand the market through research and development efforts to create new medicines and improve existing ones. According to GLOBOCAN 2020 predictions, stomach cancer caused around 800,000 deaths, accounting for 7.7% of all cancer-related mortality. It was the fourth leading cause of cancer-related mortality for both genders. In 2020, there were roughly 1.1 million newly diagnosed cases of stomach cancer, accounting for 5.6% of total cancer cases. The National Cancer Institute predicts that the number of newly diagnosed stomach cancer cases will peak at 26,500 in 2023. As a result, the predicted increase in stomach cancer cases will drive global market growth

Growing Awareness

Awareness initiatives are crucial in the stomach cancer market because they educate the general public about risk factors, symptoms, and the need of early identification. These programs raise public awareness about screening treatments such as endoscopy, genetic testing, and imaging examinations, encouraging people to get them. These programs improve patient outcomes by promoting routine screenings to detect stomach cancer in its early, more curable stages. For instance, the Stomach Cancer Foundation of Canada raises global awareness through its annual event, "The Power of Periwinkle," which takes place on November 30. Today, more than 120 locations in Europe, Asia, the United States, Canada, and Australia are lighted in periwinkle blue, the hue associated with stomach cancer awareness.

Restraint Factor for the Stomach Cancer and Gastric Cancer Treatment Market

Side Effects of Treatment

The side effects of stomach cancer treatment can have a major impact on patient well-being and adherence, limiting market growth. Chemotherapy, a cornerstone of stomach cancer treatment, frequently causes side effects such as nausea, vomiting, exhaustion, and hair loss, which can reduce patients' quality of life and necessitate treatment suspensions or dose adjustments. Similarly, radiation therapy can cause gastrointestinal issues, tiredness, and skin irritation, worsening the patients' experiences. These side effects cause not only physical suffering but also psychological distress, which may dissuade patients from seeking or continuing treatment. To manage these side effects, supportive care measures and drugs are required, which increases the overall cost and complexity of treatment.

Impact of Covid-19 on the Stomach Cancer and Gastric Cancer Treatment Market

The Covid-19 epidemic has had a substantial impact on the stomach cancer therapy market size. According to the National Center for Biotechnology Information...

Hypothesis/Commentary for This Article from Demographic Disparities in Patterns of Care and Survival Outcomes for Patients with Resected Gastric Adenocarcinoma

aχ2 test for genotype distributions between stomach cancer cases and controls.b Adjusted for age, sex, BMI, smoking and drinking status.c Additive models.d Dominant models.Logistic regression analysis of associations between the genotypes of PSCA, MUC1, PLCE1 and stomach cancer susceptibility in a Chinese population.

BackgroundEsophageal and gastric cancers are common malignant tumors of the digestive tract worldwide, characterized by a substantial disease burden and significant regional disparities. While these cancers share anatomical proximity, risk factors, and pathogenic mechanisms to some extent, there remains a lack of comprehensive and up-to-date global comparative studies on their co-occurrence patterns and burden trends.MethodsUsing primary data from the Global Burden of Disease (GBD) 2021 study, we defined and categorized global co-occurrence patterns of esophageal and gastric cancers based on quartile methods. Descriptive analysis, correlation analysis, age-period-cohort modeling, decomposition analysis, and predictive modeling were employed to thoroughly examine the disease burden of both cancers across 204 countries and territories from 1990 to 2021.ResultsThe disease burden of gastric cancer consistently exceeded that of esophageal cancer in most countries and regions. Spatially, the Eastern and Northern Hemispheres, including countries such as China and Mongolia, were identified as consistent high-burden regions for both cancers. In contrast, the Western and Southern Hemispheres were predominantly characterized by single-cancer dominance or low-burden patterns. Disease burden was negatively correlated with the Socio-demographic Index (SDI), with higher burden observed in low-SDI regions. Males and older populations faced elevated disease risks. Furthermore, population growth and aging were identified as major drivers increasing the overall burden. Predictions indicate that by 2031, the age-standardized rates of both cancers will continue to decline, yet the overall burden of gastric cancer will remain significantly higher than that of esophageal cancer.ConclusionsGastric cancer imposes a heavier disease burden than esophageal cancer across most countries and regions. These findings underscore the necessity for sustained and targeted prevention strategies, such as the promotion of healthy lifestyles, enhanced early screening, and improved healthcare accessibility in high-burden regions, to effectively reduce the global burden of esophageal and gastric cancers.

The global Stomach and Gastric Cancer Treatment market is poised for significant expansion, projected to reach an estimated market size of approximately $15,500 million by 2025, with a robust Compound Annual Growth Rate (CAGR) of XX% anticipated between 2025 and 2033. This growth trajectory is primarily propelled by advancements in targeted therapies and immunotherapies, which are revolutionizing treatment paradigms. The increasing incidence of gastric cancer, particularly in certain demographic groups and regions, coupled with a growing awareness and early detection initiatives, further fuels market demand. Key market drivers include the development of novel therapeutic agents, such as Programmed Cell Death Protein 1 (PD-1) inhibitors and Human Epidermal Growth Factor Receptor (HER2) antagonists, offering improved efficacy and reduced side effects compared to traditional chemotherapy. The expanding healthcare infrastructure, particularly in emerging economies, and the growing preference for specialized cancer treatment centers like hospitals and clinics also contribute to market dynamism. Despite the optimistic outlook, certain restraints may influence the market's pace. High treatment costs associated with advanced therapies and the potential for side effects can pose challenges to widespread adoption, especially in resource-limited settings. Stringent regulatory approval processes for new drugs can also impact market entry timelines. However, ongoing research and development efforts, strategic collaborations between pharmaceutical giants and biotechnology firms, and the increasing focus on personalized medicine are expected to mitigate these restraints. The market is segmented by therapeutic type, with PD-1 inhibitors and HER2 antagonists holding substantial shares due to their proven efficacy. Geographically, North America and Europe currently dominate the market, driven by sophisticated healthcare systems and high R&D investments. Nevertheless, the Asia Pacific region, with its large patient pool and growing healthcare expenditure, presents substantial growth opportunities for market players. This comprehensive report delves into the dynamic landscape of Stomach Cancer and Gastric Cancer Treatment, providing in-depth analysis and strategic insights for stakeholders. The global market, estimated to be worth over 15,000 million USD, is characterized by intense research and development, evolving therapeutic approaches, and significant investment from leading pharmaceutical giants. The report offers a detailed examination of treatment modalities, market segmentation, regional trends, and future projections, empowering businesses to navigate this critical sector effectively.

Legacy unique identifier: P00666

Table C. Age-specific stomach cancer deaths and the corresponding population, birth cohort and year of survey in the period 1987-2016 in Lithuania. Men